Notable ASCO Trial Data Have the Potential to Transform Oncology Pharmacy Practice

These study results may inform clinical practice strategies this year and beyond.

Related Keywords

Texas ,United States ,American ,Larry Kimmons ,Dennisj Slamon ,Emily Kuhl ,Sara Fagerlie ,Medimmune Astra Zeneca ,Astellas Pharma ,Aaron Tallent ,Kara Nyberg ,Servier Pharmaceuticals ,Department Of Gastrointestinal Medical Oncology ,Access To Oncology Medicines Coalition ,Astrazeneca ,University Of Texas Md Anderson Cancer Center ,Janssen Press ,Novartis ,Pfizer ,Department Of Investigational Cancer Therapeutics ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Annual Meeting ,Shubham Pant ,Gastrointestinal Medical Oncology ,Investigational Cancer Therapeutics ,Global Initiative ,Improve Global Patient Access ,Oncology Medicines Coalition ,Adding Ribociclib ,Endocrine Therapy May Reduce Recurrence Risk ,Hormone Receptor ,Negative Early Stage Breast ,Last Updated June ,Durvalumab Plus Olaparib ,Advanced Ovarian Cancer ,Practice Changing Results ,Platinum Resistant Ovarian Cancer ,Mirvetuximab Boosts ,Survival Benefit Seen With Erdafitinib ,Advanced Urothelial ,Updated June ,Accessed June ,Vorasidenib Delays Disease Progression ,Patients With Grade ,Reinforces Adjuvant Osimertinib ,Patients With Stage ,Mutated Non ,Small Cell Lung ,More Than ,Heavily Pretreated Patients ,Janssen Presents First Ever Results ,Dual Bispecific Combination Study Showing ,Overall Response Rate ,Refractory Multiple ,Enzalutamide Excels ,Patients With ,Lat Updated June ,Ensure Equitable Cancer Care ,